{"id":"unfractioned-heparin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bleeding"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"1-5%","effect":"Hypersensitivity reactions"},{"rate":"1-5%","effect":"Osteoporosis"}]},"_chembl":{"chemblId":"CHEMBL4650299","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to the inhibition of thrombin and factor Xa, resulting in a decrease in blood clot formation. Unfractionated heparin also has a direct effect on the coagulation cascade by binding to and activating antithrombin, which in turn inhibits the conversion of prothrombin to thrombin.","oneSentence":"Unfractionated heparin works by activating antithrombin, a protein that inhibits the coagulation cascade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:42.928Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis and treatment of deep vein thrombosis"},{"name":"Prophylaxis and treatment of pulmonary embolism"},{"name":"Prophylaxis and treatment of atrial fibrillation for stroke prevention"},{"name":"Prophylaxis and treatment of myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07285603","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229","status":"COMPLETED","sponsor":"Matisse Pharmaceuticals","startDate":"2024-11-21","conditions":"Healthy Subjects","enrollment":15},{"nctId":"NCT04861922","phase":"PHASE3","title":"Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2021-05-11","conditions":"Sepsis, Gram-Negative Bacterial Infections, Heparin","enrollment":100},{"nctId":"NCT05422170","phase":"","title":"HEParin Antagonisation in Transcatheter Aortic Valve Implantation","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2022-07-01","conditions":"Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation, Protamine Sulfate Overdose","enrollment":50},{"nctId":"NCT04487990","phase":"NA","title":"CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-06-29","conditions":"Acute Kidney Injury, Covid19","enrollment":118},{"nctId":"NCT01823393","phase":"PHASE4","title":"Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure","status":"TERMINATED","sponsor":"University Hospital, Montpellier","startDate":"2013-01-24","conditions":"Aortic Stenosis, Non-rheumatic","enrollment":94},{"nctId":"NCT03854266","phase":"PHASE2","title":"Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2020-03-10","conditions":"Pulmonary Embolism","enrollment":60},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT02531165","phase":"NA","title":"Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2015-09","conditions":"Acute Myocardial Infarction","enrollment":38},{"nctId":"NCT04048525","phase":"NA","title":"Cytokine Removal With CVVHD Compared to CVVH","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2013-03-13","conditions":"Cytokine Release Syndrome, Sepsis, AKI","enrollment":40},{"nctId":"NCT01790620","phase":"NA","title":"Impact of CVVHD With Adsorption Capacity Membranes in Septic Acute Kidney Injury","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2013-05","conditions":"Sepsis, Septic Shock, Acute Kidney Injury","enrollment":110},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT02698618","phase":"PHASE4","title":"PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor","status":"UNKNOWN","sponsor":"Fundacion Investigacion Interhospitalaria Cardiovascular","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT02181998","phase":"PHASE3","title":"A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-07","conditions":"Myocardial Infarction","enrollment":1606},{"nctId":"NCT01555658","phase":"PHASE3","title":"Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2012-04","conditions":"Coronary Artery Disease","enrollment":204},{"nctId":"NCT00398463","phase":"PHASE4","title":"Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2006-05","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":263},{"nctId":"NCT01072747","phase":"PHASE3","title":"Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2010-04","conditions":"Prevention of Venous Thromboembolism","enrollment":104},{"nctId":"NCT00448461","phase":"PHASE4","title":"Antithrombotic Regimens and Outcome","status":"COMPLETED","sponsor":"Careggi Hospital","startDate":"2007-03","conditions":"Coronary Artery Disease","enrollment":850},{"nctId":"NCT00669721","phase":"NA","title":"OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2008-03","conditions":"Renal Failure, Hemodialysis","enrollment":40},{"nctId":"NCT00100308","phase":"PHASE3","title":"Unfractioned Heparin for Treatment of Sepsis","status":"COMPLETED","sponsor":"Universidad de Antioquia","startDate":"2005-07","conditions":"Sepsis, Bacterial Infections","enrollment":319}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"THROMBOSIS IN DEVICE"},{"count":3,"reaction":"PULMONARY EMBOLISM"},{"count":3,"reaction":"THROMBOCYTOPENIA"},{"count":2,"reaction":"CATHETER SITE DISCHARGE"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"PETECHIAE"},{"count":2,"reaction":"PREMATURE DELIVERY"},{"count":2,"reaction":"RETROPERITONEAL HAEMORRHAGE"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"APALLIC SYNDROME"}],"_approvalHistory":[],"publicationCount":189,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["standard heparin, Sodic Heparin"],"phase":"phase_3","status":"active","brandName":"Unfractioned heparin","genericName":"Unfractioned heparin","companyName":"Universidad de Antioquia","companyId":"universidad-de-antioquia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Unfractionated heparin is used to prevent venous thromboembolism and is studied in conditions such as pulmonary embolism and acute kidney injury. It works by activating Antithrombin-III, a protein that inhibits blood clot formation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}